28 January 2016 -interim results
The group has announced its interim results for the six months to the end of October although these are largely meaningless given the stage of the group’s development. ANGLE continues with the development of its patented Parsortix liquid biopsy system which allows it to capture cancer cells from human blood for subsequent analysis. The group has secured the first sales of the product for research use and received additional patents in China, Australia and Canada. At the end of October the company had net cash of £5.8m and to put this in context the group reported a loss of £2.3m over the six months to that date. Although progress in the development of the system remains fairly slow the target market for the product is huge and the shares are attractive for patient investors. LONG TERM BUY.